Literature DB >> 26419509

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

B Dalla Palma1,2, D Guasco1, M Pedrazzoni1,3, M Bolzoni1, F Accardi1, F Costa1, G Sammarelli1, L Craviotto1, M De Filippo4, L Ruffini5, P Omedè6, R Ria7, F Aversa1,2, N Giuliani1,2.   

Abstract

The relationship between bone marrow (BM) cytokine and chemokine levels, cytogenetic profiles and skeletal involvement in multiple myeloma (MM) patients is not yet defined. This study investigated a cohort of 455 patients including monoclonal gammopathy of uncertain significance (MGUS), smoldering MM and symptomatic MM patients. Skeletal surveys, positron emission tomography (PET)/computerized tomography (CT) and magnetic resonance imaging (MRI) were used to identify myeloma bone disease. Significantly higher median BM levels of both C-C motif Ligand (CCL)3 and CCL20 were found in MM patients with radiographic evidence of osteolytic lesions as compared with those without, and in all MM patients with positive PET/CT scans. BM levels of CCL3, CCL20, Activin-A and Dickkopf-1 (DKK-1) were significantly higher in patients with high bone disease as compared with patients with low bone disease. Moreover, CCL20 BM levels were significant predictors of osteolysis on X-rays by multivariate logistic analysis. On the other hand, DKK-1 levels were related to the presence of MRI lesions independently of the osteolysis at the X-rays. Our data define the relationship between bone disease and the BM cytokine and chemokine patterns highlighting the tight relationship between CCL20 BM levels and osteolysis in MM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26419509     DOI: 10.1038/leu.2015.259

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  54 in total

1.  Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.

Authors:  Nicola Giuliani; Francesca Morandi; Sara Tagliaferri; Simona Colla; Sabrina Bonomini; Gabriella Sammarelli; Vittorio Rizzoli
Journal:  Blood       Date:  2006-01-15       Impact factor: 22.113

Review 2.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

Review 3.  Advances in the regulation of osteoclasts and osteoclast functions.

Authors:  B F Boyce
Journal:  J Dent Res       Date:  2013-08-01       Impact factor: 6.116

4.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

5.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Authors:  F Di Raimondo; M P Azzaro; G Palumbo; S Bagnato; G Giustolisi; P Floridia; G Sortino; R Giustolisi
Journal:  Haematologica       Date:  2000-08       Impact factor: 9.941

6.  Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.

Authors:  Maria Kraj; Katarzyna Owczarska; Urszula Sokołowska; Piotr Centkowski; Ryszard Pogłód; Barbara Kruk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2005 Sep-Oct       Impact factor: 4.291

7.  IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

Authors:  Lori A Ehrlich; Ho Yeon Chung; Irene Ghobrial; Sun Jin Choi; Francesca Morandi; Simona Colla; Vittorio Rizzoli; G David Roodman; Nicola Giuliani
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

8.  Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.

Authors:  Xiao-Tao Wang; Yu-Chan He; Si-Yao Zhou; Jing-zi Jiang; Yu-Mei Huang; Yu-Zhen Liang; Yong-Rong Lai
Journal:  Leuk Res       Date:  2014-03-06       Impact factor: 3.156

9.  Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

Authors:  R Bataille; D Chappard; M F Basle
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

10.  Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis.

Authors:  Nicola E Annels; Cristiana E T Da Costa; Frans A Prins; Annemieke Willemze; Pancras C W Hogendoorn; R Maarten Egeler
Journal:  J Exp Med       Date:  2003-05-12       Impact factor: 14.307

View more
  28 in total

1.  CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion.

Authors:  Junhee Park; Xianglan Zhang; Sun Kyoung Lee; Na-Young Song; Seung Hwa Son; Ki Rim Kim; Jae Hoon Shim; Kwang-Kyun Park; Won-Yoon Chung
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

2.  Hereditary breast cancer: screening and risk reducing surgery.

Authors:  Matteo Renzulli; Simone Zanotti; Alfredo Clemente; Giangaspare Mineo; Francesco Tovoli; Alfonso Reginelli; Antonio Barile; Salvatore Cappabianca; Mario Taffurelli; Rita Golfieri
Journal:  Gland Surg       Date:  2019-09

3.  Does multiparametric US improve diagnostic accuracy in the characterization of small testicular masses?

Authors:  Alfonso Reginelli; Alfredo D'Andrea; Alfredo Clemente; Andrea Izzo; Fabrizio Urraro; Fernando Scala; Valerio Nardone; Cesare Guida; Michele Scialpi; Salvatore Cappabianca
Journal:  Gland Surg       Date:  2019-09

4.  Delayed enhancement in differential diagnosis of salivary gland neoplasm.

Authors:  Alfonso Reginelli; Alfredo Clemente; Matteo Renzulli; Nicola Maggialetti; Mario Santagata; Giuseppe Colella; Valerio Nardone; Rita Golfieri; Luca Brunese; Salvatore Cappabianca
Journal:  Gland Surg       Date:  2019-09

5.  Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.

Authors:  Oliver C Goodyear; Sarah Essex; Anandram Seetharam; Supratik Basu; Paul Moss; Guy Pratt
Journal:  Oncotarget       Date:  2017-05-02

6.  IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Authors:  Marina Bolzoni; Domenica Ronchetti; Paola Storti; Gaetano Donofrio; Valentina Marchica; Federica Costa; Luca Agnelli; Denise Toscani; Rosanna Vescovini; Katia Todoerti; Sabrina Bonomini; Gabriella Sammarelli; Andrea Vecchi; Daniela Guasco; Fabrizio Accardi; Benedetta Dalla Palma; Barbara Gamberi; Carlo Ferrari; Antonino Neri; Franco Aversa; Nicola Giuliani
Journal:  Haematologica       Date:  2017-01-05       Impact factor: 9.941

Review 7.  Receptor binding competition: A paradigm for regulating TGF-β family action.

Authors:  Erik Martinez-Hackert; Anders Sundan; Toril Holien
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-06       Impact factor: 7.638

Review 8.  Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells.

Authors:  Carolyne Falank; Heather Fairfield; Michaela R Reagan
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-17       Impact factor: 5.555

Review 9.  Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2018-01-12       Impact factor: 11.037

10.  Neurofibromatosis type I and multiple myeloma coexistence: A possible link?

Authors:  Fabrizio Accardi; Valentina Marchica; Cristina Mancini; Elena Maredi; Costantina Racano; Laura Notarfranchi; Davide Martorana; Paola Storti; Eugenia Martella; Benedetta Dalla Palma; Luisa Craviotto; Massimo De Filippo; Antonio Percesepe; Franco Aversa; Nicola Giuliani
Journal:  Hematol Rep       Date:  2018-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.